Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Evotec SE's share price for the quarter that ended in Dec. 2023 was $11.73. Evotec SE's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 354.4 Mil. Therefore, Evotec SE's market cap for the quarter that ended in Dec. 2023 was $4,156.8 Mil.
Evotec SE's quarterly market cap
declined
from Jun. 2023 ($4,004.4 Mil) to Sep. 2023 ($3,497.6 Mil) but then
increased
from Sep. 2023 ($3,497.6 Mil) to Dec. 2023 ($4,156.8 Mil).
Evotec SE's annual market cap
declined
from Dec. 2021 ($8,388.9 Mil) to Dec. 2022 ($2,863.1 Mil) but then
increased
from Dec. 2022 ($2,863.1 Mil) to Dec. 2023 ($4,156.8 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Evotec SE's Enterprise Value for Today is $1,856.4 Mil.
Evotec SE Market Cap Historical Data
The historical data trend for Evotec SE's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Evotec SE's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evotec SE's Market Cap Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Evotec SE's Market Cap distribution charts can be found below:
* The bar in red indicates where Evotec SE's Market Cap falls into.
Evotec SE Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Evotec SE's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evotec SE (NAS:EVO) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Evotec SE Market Cap Related Terms
Thank you for viewing the detailed overview of Evotec SE's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Evotec SE is a drug discovery partnership company providing solutions to pharmaceutical & biotechnology companies, academic institutions as well as foundations, and not-for-profit organizations. The company offers its services in the area of neuronal diseases, diabetes & its complications, pain, inflammation, oncology, infectious diseases, respiratory & fibrosis, rare disease, and women's health. Its business segments are EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone drug discovery services on a typical fee-for-service basis or integrated drug discovery collaborations. The EVT Innovate segment develops drug discovery programs and assets, both internally and through academic collaborations. The majority of its revenue is derived from the EVT Execute segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
EVO has been successfully added to your 